Biomedical research has rushed headlong into commercial foundation models across clinical decision support, diagnostic triage, documentation, and drug discovery pipelines. Unlike classic biomedical machine learning—which leaned on versioned statistical packages and self-contained, locally executable codebases—modern workflows increasingly run on proprietary cloud endpoints. This shift creates a severe operational mismatch: evidence-based clinical medicine demands absolute experimental immutability, while cloud vendors routinely deprecate and decommission hosted model versions according to their own commercial roadmaps.
According to an investigation led by Dr. Nathan Wolfrath, Dr. Meghan Conroy, and corresponding author Dr. Anai N. Kothari from the Medical College of Wisconsin alongside researchers from Marquette University, commercial lifecycle policies are gutting the empirical foundation of medical AI. Once a proprietary endpoint goes dark, external scientific validation stops dead: independent investigators and regulators lose access to the exact computational engine responsible for the published clinical metrics.
Quantifying the Vanishing Model Footprint
To gauge the scale of this vulnerability, the authors analyzed PubMed publications between 2022 and March 2026 that applied specific large language models to biomedical workloads. From 61,077 abstracts processed via an extraction agent and verified by human reviewers, the researchers isolated 8,931 paper-model mentions across 5,242 unique papers covering the top 50 most frequently used models.
Proprietary, closed-weight systems dominated 77.7% of all mentions, underscoring an acute dependence on hosted vendor infrastructure over on-premise deployments. OpenAI systems, including ChatGPT variants, accounted for roughly 66% of models cited in clinical literature between January 2022 and September 2025.
"Many biomedical publications using LLMs are on a trajectory toward computational non-reproducibility after publication."
The consequences are immediate: 42% of analyzed mentions relied on an endpoint that was already retired by the official publication date or scheduled for retirement within two years. More critically, the median lifespan from formal publication to endpoint shutdown was just 538 days. In practice, the core algorithmic mechanism behind peer-reviewed clinical claims evaporates in under eighteen months.
What this means:
For CTOs, healthcare R&D executives, and regulatory leaders, this rapid deprecation timeline shatters the entire framework of retrospective auditing and regulatory defense. When proprietary endpoints vanish in fewer than 538 days, safety verifications and algorithmic audit trails disappear with them. Bridging this structural gap between academic timelines and cloud vendor product lifecycles leaves enterprise leaders with two clear options: migrate regulated biomedical workloads to self-hosted, open-weight architectures, or negotiate strict, long-term vendor SLAs that guarantee permanent endpoint immutability for retrospective compliance.